This is a summary of the European public assessment report (EPAR) for Tarceva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tarceva.
- What is Tarceva?
Tarceva is a cancer medicine that contains the active substance erlotinib. It is available as tablets (25, 100 and 150 mg).
- What is Tarceva used for?
Tarceva is used in non‑small-cell lung cancer (NSCLC) that is ‘advanced’ (the cancer has started to spread) or ‘metastatic’ (it has already spread to other parts of the body). It is used in the following patients:
- patients whose cancer cells have certain changes ('activating mutations’) in the gene for a protein called epidermal growth factor receptor (EGFR) and have not received previous chemotherapy (medicines to treat cancer);
- patients with EGFR activating mutations whose disease is stable after initial chemotherapy. ‘Stable’ means that the cancer had neither improved nor worsened during the chemotherapy;
- patients who have had at least one previous chemotherapy treatment that has failed.
Tarceva has not been shown to be effective in patients whose lung cancer is ‘EGFR IHC-negative’. ‘EGFR IHC-negative’ means that the EGFR receptor protein cannot be detected on the surface of the cancer cells, or can only be detected in small quantities.
Tarceva is also used in patients with metastatic pancreatic cancer, in combination with gemcitabine (another cancer medicine).
For both lung cancer and pancreatic cancer, doctors should take the patient’s chances of survival into account when prescribing Tarceva.
The medicine can only be obtained with a prescription.
- How is Tarceva used?
Treatment with Tarceva should be supervised by a doctor who has experience in the use of cancer medicines. In patients who have not yet received chemotherapy, EGFR mutation testing should be performed before starting Tarceva therapy.
For lung cancer, the recommended daily dose of Tarceva is 150 mg. For pancreatic cancer, it is 100 mg. Tarceva is taken at least one hour before or two hours after food. If needed (for example because of side effects), the dose may be reduced in 50‑mg steps. As Tarceva seems to be more effective in patients with pancreatic cancer who develop a rash, treatment should be re‑assessed after four to eight weeks if no rash has developed. Patients taking Tarceva should stop smoking, as smoking can decrease the amount of the medicine in the blood.
- How does Tarceva work?
The active substance in Tarceva, erlotinib, is a cancer medicine that belongs to the group ‘EGFR inhibitors’. Erlotinib blocks EGFRs, which can be found on the surface of some tumour cells. As a result of this block, the tumour cells can no longer receive the messages needed for growth, progression and spreading (metastasis). As a result, Tarceva helps to stop the cancer from growing, multiplying and spreading through the body.
- How has Tarceva been studied?
In non-small cell lung cancer Tarceva has been mainly studied in four studies:
- the first study compared Tarceva with other chemotherapy in 173 patients with advanced NSCLC with activating EGFR mutations who had not received previous chemotherapy.
- the second study involved 889 patients with NSCLC whose disease had not got worse following an initial course of treatment with four cycles of platinum-containing chemotherapy, 487 of whom had stable disease; in this study, a subgroup of 49 patients had activating EGFR mutations. This study compared Tarceva with placebo (a dummy treatment).
- a third study compared Tarceva with placebo in 643 patients with advanced NSCLC whose cancer cells did not have EGFR activating mutations and whose disease was stable after initial treatment with four cycles of platinum-containing chemotherapy. The study compared how long patients survived when Tarceva was used early in the study with how long they survived when Tarceva was used later in the study.
- the fourth study involved 731 patients who had not responded to at least one previous chemotherapy treatment; this study compared Tarceva to placebo.
In pancreatic cancer, Tarceva in combination with gemcitabine has been studied in 569 patients with pancreatic cancer that was advanced, unresectable (that cannot be removed by surgery) or metastatic.
In all of the studies, the main measure of effectiveness was how long the patients lived without their cancer getting worse or how long they survived.
- What benefit has Tarceva shown during the studies?
In the first study, in lung cancer patients with EGFR activating mutations, patients taking Tarceva as initial treatment survived without their disease getting worse for an average of 9.7 months compared with 5.2 months for those receiving other chemotherapy medicines.
In the overall population of the second study (889 patients), Tarceva caused a marginal increase in how long the patients lived without their disease getting worse and in how long they survived. The greatest benefit was observed in the subgroup of 49 patients with EGFR activating mutations: those taking Tarceva (22 patients) lived for an average of 44.6 weeks without their disease getting worse, compared with 13 weeks for those taking placebo (27 patients).
The third study did not support the early use of Tarceva in lung cancer patients without EGFR activating mutations, including patients with stable disease: the study found no advantage to early use of the medicine, as patients treated with Tarceva early in the study did not live longer than those treated with Tarceva later in the study (after the disease had progressed).
In the fourth study, in lung cancer patients who had not responded to previous chemotherapy, the patients taking Tarceva survived for an average of 6.7 months, compared with 4.7 months for the patients taking placebo. Among the patients who took Tarceva, the average survival was 8.6 months in those whose tumours were ‘EGFR IHC-positive’ (had EGFRs on their surface), and 5.0 months in those whose tumours were EGFR IHC-negative.
In the study in metastatic pancreatic cancer, patients taking Tarceva as initial therapy survived without their disease getting worse for an average of 5.9 months, compared with 5.1 months in those taking placebo. However, there was no advantage for patients whose cancer had not spread beyond the pancreas.
- What is the risk associated with Tarceva?
In studies, the most common side effects with Tarceva when used as monotherapy for lung cancer were rash (seen in 75% of patients), diarrhoea (seen in 54% of patients), loss of appetite and tiredness (each seen in 52% of patients). In the study of Tarceva used in combination with gemcitabine for pancreatic cancer, the most common side effects were tiredness (seen in 73% of patients), rash (seen in 69% of patients) and diarrhoea (seen in 48% of patients). Patients with persistent and severe diarrhoea, nausea, loss of appetite, or vomiting should contact their doctor, as they may be at risk of low blood potassium levels and kidney failure. They may need to be treated in hospital.
For the full list of side effects and restrictions with Tarceva, see the package leaflet.
- Why has Tarceva been approved?
The CHMP decided that Tarceva’s benefits are greater than its risks and recommended that it be given marketing authorisation.
- What measures are being taken to ensure the safe and effective use of Tarceva?
A risk management plan has been developed to ensure that Tarceva is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Tarceva, including the appropriate precautions to be followed by healthcare professionals and patients.
- Other information about Tarceva
The European Commission granted a marketing authorisation valid throughout the European Union for Tarceva on 19 September 2005.
For more information about treatment with Tarceva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
This EPAR was last updated on 12/08/2016 .
21/07/2016 Tarceva -EMEA/H/C/000618 -N/0047
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Non-small cell lung cancer (NSCLC)
Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.
Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
When prescribing Tarceva, factors associated with prolonged survival should be taken into account.
No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours (see section 5.1).
Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.
When prescribing Tarceva, factors associated with prolonged survival should be taken into account (see section 4.2 and 5.1).
Changes since initial authorisation of medicine
Initial marketing-authorisation documents
|Name||Language||First published||Last updated|
|Tarceva : EPAR - Procedural steps taken before authorisation||NO = Norsk||02/11/2005|
|Tarceva : EPAR - Scientific Discussion||NO = Norsk||02/11/2005|
This medicine is approved for use in the European Union